Contribution of Massive Parallel Sequencing to Diagnosis of Hereditary Ovarian Cancer in the Czech Republic

Česká verzia

Authors: Jana Soukupová ¹; Klára Lhotová ¹; Petra Zemánková ¹; Michal Vočka ²; Markéta Janatová ¹; Lenka Stolařová ¹; Marianna Borecká ¹; Petra Kleiblová ³; Eva Macháčková ⁴; Lenka Foretová ⁴; Monika Koudová ⁵; Filip Lhota ⁵; Spiros Tavandzis ⁶; Michal Zikán ⁷; Viktor Stránecký ⁸; Kamila Veselá ³; Aleš Panczak ^3,9; Jaroslav Kotlas ³; Zdeněk Kleibl ¹
Authors place of work: Ústav biochemie a experimentální onkologie, 1. LF UK v Praze ¹; Onkologická klinika 1. LF UK a VFN v Praze ²; Ústav biologie a lékařské genetiky, 1. LF UK a VFN v Praze ³; Oddělení epidemiologie a genetiky nádorů, Masarykův onkologický ústav, Brno ⁴; Centrum lékařské genetiky a reprodukční medicíny GENNET, Praha ⁵; Oddělení lékařské genetiky, Laboratoře AGEL, Nový Jičín ⁶; Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce, Praha ⁷; Ústav dědičných metabolických poruch, 1. LF UK a VFN v Praze ⁸; Radioterapeutická a onkologická klinika FN Královské Vinohrady, Praha ⁹
Published in the journal: Klin Onkol 2019; 32(Supplementum2): 72-78
Category: Original Articles
doi: https://doi.org/10.14735/amko2019S72

Summary

Background: Ovarian cancer is a disease with high mortality. Approximately 1,000 women are diagnosed with ovarian cancer in the Czech Republic annually. Women harboring a mutation in cancer-predisposing genes face an increased risk of tumor development. Mutations in BRCA1, BRCA2, BRIP1, and Lynch syndrome genes (RAD51C, RAD51D, and STK11) are associated with a high risk of ovarian cancer, and mutations in ATM, CHEK2, NBN, PALB2, and BARD1 appear to increase the risk. Our aim was to examine the frequency of mutations in cancer-predisposing genes in the Czech Republic.

Materials and methods: We analyzed 1,057 individuals including ovarian cancer patients and 617 non-cancer controls using CZECANCA panel next-generation sequencing on the Illumina platform. Pathogenic mutations in high-risk genes, including CNVs, were detected in 30.6% of patients. The mutation frequency reached 25.0% and 18.2% in subgroups of unselected ovarian cancer patients and patients with a negative family cancer history, respectively. The most frequently mutated genes were BRCA1 and BRCA2. The overall frequency of mutations in non-BRCA genes was comparable to that in BRCA2. The mutation frequency in ovarian cancer patients aged >70 years was three times higher than that in patients diagnosed before the age of 30.

Conclusion: Ovarian cancer is a heterogeneous disease with a high proportion of hereditary cases. The lack of efficient screening for early diagnosis emphasizes the importance of identifying carriers of mutations in ovarian cancer-predisposing genes; this is because proper follow-up and prevention strategies can reduce overall ovarian cancer-related mortality.

This work was supported by grants AZV 15-27695A, SVV2019/260367, PROGRES Q28/LF1.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted: 7. 3. 2019

Accepted: 24. 4. 2019

Keywords:

Mutation – ovarian neoplasms – cancer genes – massively-parallel sequencing – next generation sequencing – gene panel

Zdroje

1. uzis.cz. Ústav zdravotnických informací a statistiky ČR. [online]. Dostupný z http: //www.uzis.cz.

2. Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 2012; 124 (2): 347–353. doi: 10.1016/j.ygyno.2011.12.415.

3. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72 (5): 1117–1130. doi: 10.1086/375033.

4. nccn.org. National Comprehensive Cancer Network; version 3.2019. [online]. Available from: https: //www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.

5. Soukupová J. Úskalí interpretace sekvenačních dat v diagnostice dědičných nádorových syndromů. Labor Aktuell 2016; 20 (4): 4.

6. Soukupová J, Zemánková P, Lhotová K et al. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PLoS One 2018; 13 (4): e0195761. doi: 10.1371/journal.pone.0195761.

7. Soukupová J, Zemánková P, Kleiblová P et al. CZECANCA: CZEch CAncer paNel for Clinical Application – návrh a příprava cíleného sekvenačního panelu pro identifikaci nádorové predispozice u rizikových osob v České republice. Klin Onkol 2016; 29 (Suppl 1): S46–S54. doi: 10.14735/amko2016S46.

8. internationalgenome.org. The 1000 Genomes Browser. [online]. Available from: http: //www.internationalgenome.org/1000-genomes-browsers.

9. enigmaconsortium.org. ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles). [online]. Available from: https: //enigmaconsortium.org/.

10. ncbi.nlm.nih.gov. ClinVar. [online]. Available from: https: //www.ncbi.nlm.nih.gov/clinvar/.

11. Nielsen SM, Eccles DM, Romero IL et al. Genetic testing and clinical management practices for variants in non-BRCA1/2 breast (and breast/ovarian) cancer susceptibility genes: an international survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) clinical working group. J Clin Oncol 2018; 36 (2): 1–42.

12. Norquist BM, Harrel MI, Brady MF et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016; 2 (4): 482–90. doi: 10.1001/jamaoncol.2015.5495.

13. Weber-Lassalle N, Hauke J, Ramser J et al. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Res 2018; 20 (1): 7. doi: 10.1186/s13058-018-0935-9.

14. Walsh T, Casadei S, Lee MK et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011; 108 (44): 18032–18037. doi: 10.1073/pnas.1115052108.

15. Carter NJ, Marshall ML, Susswein LR et al. Germline pathogenic variants identified in women with ovarian tumors. Gynecol Oncol 2018; 151 (3): 481–488. doi: 10.1016/j.ygyno.2018.09.030.

16. Foretová L, Macháčková E, Palácová M et al. Doporučení rozšíření indikačních kriterií ke genetickému testování mutací v genech BRCA1 a BRCA2 u hereditárního syndromu nádorů prsu a ovarií. Klin Onkol 2016; 29 (Suppl 1): S9–S13. doi: 10.14735/amko2016S9.

17. Plevová P, Novotný J, Petráková K et al. Syndrom hereditárního karcinomu prsu a ovarií. Klin onkol 2009; 22 (Suppl 1): S8–S11.

18. Petráková K, Palácová M, Schneiderová M et al. Syndrom hereditárního karcinomu prsu a ovarií. Klin Onkol 2016; 29 (Suppl 1): S14–S21. doi: 10.14735/amko2016 S14.

19. Zikán M. Gynekologická prevence a gynekologické aspekty péče u nosiček mutací genů BRCA1 a BRCA2. Klin Onkol 2016; 29 (Suppl 1): S22–S30. doi: 10.14735/amko2016S22.

20. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26 (32): 5284–93. doi: 10.1200/JCO.2008.18.1107.

21. Morgan RD, Clamp AR, Evans DG et al. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother Pharmacol 2018; 81 (4): 647–658. doi: 10.1007/s00280-018-3532-9.